GLP-1 receptor agonists and SGLT2 inhibitors: The need to shed light on their safety risks real dimension and possible mechanisms-Reference-Cited by-同舟云学术

GLP-1 receptor agonists and SGLT2 inhibitors: The need to shed light on their safety risks real dimension and possible mechanisms

Published:2023-08 Issue:8 Volume:37 Page:108553
ISSN:1056-8727
Container-title:Journal of Diabetes and its Complications
language:en
Short-container-title:Journal of Diabetes and its Complications

Author:

Gómez-Peralta Fernando,Abreu Cristina,Rizzo Manfredi

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference31 articles.

1. Home, Resources, diabetes L with, et al. IDF Diabetes Atlas 2021 | IDF Diabetes Atlas. Accessed June 3, 2023. https://diabetesatlas.org/atlas/tenth-edition/.

2. Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: recommendations from a Eastern and Southern Europe diabetes expert group;Janez;Int J Cardiol,2022

3. Filling the gap between guidelines and real world in the cardiovascular approach to the diabetic patients: the need for a call to action;Maranta;Int J Cardiol,2021

4. From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes;Mosenzon;Cardiovasc Diabetol,2021

5. Review of SGLT2i for the treatment of renal complications: experience in patients with and without T2D;González-Albarrán;Diabetes Ther,2022

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Potential of Sodium-glucose Co-transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists for Patients with Acute Coronary Syndrome: A Review of Clinical Evidence;Current Pharmaceutical Design;2024-08

2. Managing cardio-renal-metabolic risk in patients with type 2 diabetes: the role of finerenone;Journal of Diabetes and its Complications;2024-05